Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth

Background Prostate cancer (PCa) diagnosis by means of multiparametric magnetic resonance imaging (mpMRI) is a current challenge for the development of computer-aided detection (CAD) tools. An innovative CAD-software (Watson Elementary™) was proposed to achieve high sensitivity and specificity, as well as to allege a correlate to Gleason grade. Aim/Objective To assess the performance of Watson Elementary™ in automated PCa diagnosis in our hospital´s database of MRI-guided prostate biopsies. Methods The evaluation was retrospective for 104 lesions (47 PCa, 57 benign) from 79, 64.61±6.64 year old patients using 3T T2-weighted imaging, Apparent Diffusion Coefficient (ADC) maps and dynamic contrast enhancement series. Watson Elementary™ utilizes signal intensity, diffusion properties and kinetic profile to compute a proportional Gleason grade predictor, termed Malignancy Attention Index (MAI). The analysis focused on (i) the CAD sensitivity and specificity to classify suspect lesions and (ii) the MAI correlation with the histopathological ground truth. Results The software revealed a sensitivity of 46.80% for PCa classification. The specificity for PCa was found to be 75.43% with a positive predictive value of 61.11%, a negative predictive value of 63.23% and a false discovery rate of 38.89%. CAD classified PCa and benign lesions with equal probability (P 0.06, χ2 test). Accordingly, receiver operating characteristic analysis suggests a poor predictive value for MAI with an area under curve of 0.65 (P 0.02), which is not superior to the performance of board certified observers. Moreover, MAI revealed no significant correlation with Gleason grade (P 0.60, Pearson´s correlation). Conclusion The tested CAD software for mpMRI analysis was a weak PCa biomarker in this dataset. Targeted prostate biopsy and histology remains the gold standard for prostate cancer diagnosis.

[1]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[2]  Nico Karssemeijer,et al.  Clinical evaluation of a computer-aided diagnosis system for determining cancer aggressiveness in prostate MRI , 2015, European Radiology.

[3]  G J Parker,et al.  Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imaging. , 1999, Topics in magnetic resonance imaging : TMRI.

[4]  Tae Heon Kim,et al.  Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance , 2015, European Radiology.

[5]  J. Speight,et al.  Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Roethke,et al.  Evaluation of an Automated Analysis Tool for Prostate Cancer Prediction Using Multiparametric Magnetic Resonance Imaging , 2016, PloS one.

[7]  X. Filella,et al.  Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers , 2016, International journal of molecular sciences.

[8]  P. Choyke,et al.  Decision support system for localizing prostate cancer based on multiparametric magnetic resonance imaging. , 2012, Medical physics.

[9]  Karen E. Burtt,et al.  Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research , 2014, BioMed research international.

[10]  H. Ahmed,et al.  The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial , 2016, Prostate Cancer and Prostatic Diseases.

[11]  P. Humphrey,et al.  Usual and Unusual Histologic Patterns of High Gleason Score 8 to 10 Adenocarcinoma of the Prostate in Needle Biopsy Tissue , 2012, The American journal of surgical pathology.

[12]  Michael J. Barry,et al.  Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. , 2014, JAMA.

[13]  G. Litjens,et al.  Prostate Cancer: The European Society of Urogenital Radiology Prostate Imaging Reporting and Data System Criteria for Predicting Extraprostatic Extension by Using 3-T Multiparametric MR Imaging. , 2015, Radiology.

[14]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[15]  Baris Turkbey,et al.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.

[16]  M. Emberton,et al.  Management of low risk prostate cancer: active surveillance and focal therapy , 2014, Current opinion in urology.

[17]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[18]  D. Rabah,et al.  Prostate cancer screening in a Saudi population: an explanatory trial study , 2010, Prostate Cancer and Prostatic Diseases.

[19]  Masoom A Haider,et al.  Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[20]  Mehdi Moradi,et al.  Multiparametric MRI maps for detection and grading of dominant prostate tumors , 2012, Journal of magnetic resonance imaging : JMRI.

[21]  Daniele Regge,et al.  Multiparametric magnetic resonance imaging of the prostate with computer-aided detection: experienced observer performance study , 2017, European Radiology.

[22]  J. Epstein,et al.  Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies , 2016, The American journal of surgical pathology.

[23]  M. Giger,et al.  Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score--a computer-aided diagnosis development study. , 2013, Radiology.

[24]  W. Ellis,et al.  Extreme Gleason Upgrading From Biopsy to Radical Prostatectomy: A Population-based Analysis. , 2016, Urology.

[25]  G. Pron.  Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis. , 2015, Ontario health technology assessment series.

[26]  A. D'Amico,et al.  American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.

[27]  J. Hugosson,et al.  Population‐based screening for prostate cancer by measuring free and total serum prostate‐specific antigen in Sweden , 2003, BJU international.

[28]  M. Roethke,et al.  Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla , 2014, European Radiology.

[29]  R E Lenkinski,et al.  Current role of MR imaging in the staging of adenocarcinoma of the prostate. , 1993, Radiology.

[30]  Tobias Franiel,et al.  Assessment of PI-RADS v2 for the Detection of Prostate Cancer. , 2016, European journal of radiology.

[31]  Stephan E Maier,et al.  Multiparametric MRI of prostate cancer: An update on state‐of‐the‐art techniques and their performance in detecting and localizing prostate cancer , 2013, Journal of magnetic resonance imaging : JMRI.

[32]  T. Metens,et al.  What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T? , 2012, European Radiology.

[33]  Bernadette Coles,et al.  The clinical management of patients with a small volume of prostatic cancer on biopsy: What are the risks of progression? , 2008, Cancer.

[34]  Howard I. Scher,et al.  High-risk prostate cancer—classification and therapy , 2014, Nature Reviews Clinical Oncology.

[35]  C. Kim,et al.  High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2. , 2010, AJR. American journal of roentgenology.

[36]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[37]  B. K. Park,et al.  Diffusion-Weighted Magnetic Resonance Imaging for the Evaluation of Prostate Cancer: Optimal B Value at 3T , 2012, Korean journal of radiology.

[38]  Andrew B Rosenkrantz,et al.  Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. , 2014, The Journal of urology.

[39]  Gary Liney,et al.  Correlation of diffusion‐weighted magnetic resonance data with cellularity in prostate cancer , 2009, BJU international.

[40]  Nico Karssemeijer,et al.  Computer-Aided Detection of Prostate Cancer in MRI , 2014, IEEE Transactions on Medical Imaging.

[41]  M. Emberton,et al.  Management of low risk prostate cancer—active surveillance and focal therapy , 2014, Nature Reviews Clinical Oncology.

[42]  Gary P Liney,et al.  Correlation of ADC and T2 Measurements With Cell Density in Prostate Cancer at 3.0 Tesla , 2009, Investigative radiology.

[43]  J. Witjes,et al.  Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. , 2015, European urology.

[44]  Thomas Hambrock,et al.  Multiparametric Magnetic Resonance Imaging for Discriminating Low-Grade From High-Grade Prostate Cancer , 2015, Investigative radiology.

[45]  Joachim M. Buhmann,et al.  Prostate MRI Segmentation Using Learned Semantic Knowledge and Graph Cuts , 2014, IEEE Transactions on Biomedical Engineering.

[46]  M. Knopp,et al.  Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols , 1999, Journal of magnetic resonance imaging : JMRI.

[47]  David D. Casalino,et al.  Dramatic increase in the utilization of multiparametric magnetic resonance imaging for detection and management of prostate cancer , 2017, Abdominal Radiology.

[48]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[49]  Rajan T. Gupta,et al.  Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three‐dimensional transperineal template mapping histopathology , 2017, International journal of urology : official journal of the Japanese Urological Association.

[50]  Thomas Hambrock,et al.  Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. , 2011, Radiology.